Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Aprocitentan (Primary) ; Lisinopril
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 04 Dec 2017 According to a Idorsia media release, the study was completed in May 2017.
- 22 May 2017 Results published in an Actelion Pharmaceuticals media release.
- 09 May 2017 Status changed from active, no longer recruiting to completed.